SIREN : 844728808
INPHARM is a French company founded 7 years ago, specialized in the sector Ingénierie, études techniques. Based in LIMONEST (69760), this company of category PME shows in 2025 a net income positive of 194 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicador | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Ingresos | N/C | N/C | N/C | N/C |
| Resultado neto | 193 661 € | 244 062 € | 282 180 € | 210 734 € |
| EBITDA | N/C | N/C | N/C | N/C |
| Margen neto | N/C | N/C | N/C | N/C |
In 2025, INPHARM generates positive net income of 194 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2022-2025: 211 k€ -> 194 k€.
193 661 €
The debt ratio (= Financial debt / Equity x 100) stands at 10%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 57%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
9.54%
57.005%
72.3%
In 2025, the debt ratio of INPHARM (9.54) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2025, the financial autonomy of INPHARM (57.0%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
The liquidity ratio (= Current assets / Current liabilities) stands at 244.03. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
244.035
In 2025, the liquidity ratio of INPHARM (244.03) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Indicative estimate only : the number of comparable transactions in this sector is limited (34 transactions). This range of 99 403€ to 622 218€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 34 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare INPHARM with other companies in the same sector:
Voir toutes les statistiques du secteur Ingénierie, études techniques
The revenue of INPHARM is not publicly disclosed (confidential accounts filed with INPI).
Yes, INPHARM generated a net profit of 194 k€ in 2025.
The headquarters of INPHARM is located in LIMONEST (69760), in the department Rhone.
The tax return of INPHARM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
INPHARM operates in the sector Ingénierie, études techniques (NAF code 71.12B). See the 'Sector positioning' section above to compare the company with its competitors.